The first consensus document of the Spanish Society of Rheumatology on the use of TNF-α antagonists in spondyloarthritis;Primer documento de consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF-α en las espondiloartritis

Reumatologia Clinica

Volumn 1, Issue 1, 2005, Pages 32-37

  Mulero, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951627552     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(05)72710-8     Document Type: Article

References (41)

1. Van der Linden S., and Van der Heijden D. Classification of spondyloarthropathies. In: Hochberg M.C., Silman A.J., Smolen J.S., Weinblatt M.E., and Weissman M.H. (Eds). Rheumatology (2003), Mosby (Elsevier), Edinburgh 1149-1151
2. Dougados M., Van der Linden S.M., Jhulin R., Huitfeld B., Amon B., Colin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991) 1218-1227
3. Amor B., Dougados M., and Mijiyawa M. Critères de classification des Spondylarthropathies. Rev Rhum Mal Ost 57 (1990) 85-89
4. Braun J., Bollow M., Eggens R.G., Distler R.M., et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donnors. Arthritis Rheum 41 (1998) 58-67
5. Gran J.T., and Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22 (1993) 319-334
6. Braun J., and Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20 28 (2002) S16-22
7. Koehler L., Kuipers J.G., and Zeidler H. Managing seronegative spondarthritides. Rheumatology 39 (2000) 360-368
8. Clegg D.O., Reda D.J., and Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42 (1999) 2325-2329
9. Mease P.J. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 16 (2004) 366-370
10. Van der Heijde D., Dijkmans B., Geusens P., Sieper J., Dewoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52 (2005) 582-591
11. Gorman J.D., Sack K.E., and Davis J.D. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 346 (2002) 1349-1356
12. Calin A., Dijkmans B.A., Emery P., Hakala M., Kalden J., Leirisalo-Repo M., et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63 (2004) 1594-1600
13. Antoni CE, Krueger GC, De Vlam K, Birba C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. Published Online First January 27th, 2005.doi:10.1136/ard.2004.032268.
14. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
15. Rodríguez-Valverde V., Álvaro-Gracia J.M., Andreu J.L., Batlle J., and Tornero J. Segunda actualización del consenso de la Sociedad Española de Reumatología sobre la terapia biológica en artritis reumatoide. Rev Esp Reumatol 31 (2004) 394-401
16. Heuft-Dorenbosch L., Van Tubergen A., Spoorenberg A., Landewe R., Dougados M., Mielants H., et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 51 (2004) 154-159
17. Garret S.L., Jenkinson T.R., Whitelock H.C., Kennedy L.G., Gainsford G., and Calin A. A new approach to defining disease status in ankylosing spondylitis. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol 21 (1994) 2286-2291
18. Ariza-Ariza R., Hernández-Cruz B., and Navarro-Sarabia F. La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad en pacientes con espondilitis anquilosante. Rev Esp Reumatol 31 (2004) 372-378
19. Stone M.A., Inman R.D., Wright J.G., and Maetzel A. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 51 (2004) 316-320
20. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea A.J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21 (1994) 2281-2285
21. Anderson J.J., Baron G., Van der Heijde D., Nelson D.T., and Dougados M. Ankylosing spondylitis assessment group preliminary definition of shortterm improvement in ankylosing spondylitis. Arthritis Rheum 44 (2001) 1876-1886
22. Gottenberg J.E., Merle-Vicent F., Bentaberry F., Allanore Y., Berenbaum F., Fautrel B., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 48 (2003) 2019-2024
23. Rosenbaum J.T., and Smith J.R. Anti-TNFá therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 20 Suppl 28 (2002) S143-S145
24. Tan A.L., Marzo-Ortega H., O'Connor P., Fraser A., Emery P., and McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63 (2004) 1041-1045
25. Chew A.L., Bennett A., Smith C.H., Barker J., and Kirkham B. Successful treatment of severe psoriasis and psoriasis arthritis with adalimumab. Br J Dermatol 151 (2004) 492-496
26. Dougados M., Behier J.M., Jolchine I., Calin A., Van der Heijde D., Olivieri I., et al. Efficacy of celecoxib, a ciclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. Arthritis Rheum 44 (2001) 180-185
27. Van der Heijde D., Baraf H.S.B., Ramos-Remus C., Colin A., Weaver A.L., Schiff M., et al. Evaluation of the efficacy of eterocoxib in ankylosing spondylitis. Arthristis Rheum 52 (2005) 1205-1215
28. Abu-Shakra M., Gladman D.D., Thorne J.C., Long J., and Farewell V.T. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22 (1995) 241-245
29. Dougados M., Van der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38 (1995) 618-627
30. Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50 (2004) 1939-1950
31. Fraser A.D., Van Kuijk A.W., Westhovens R., Karim Z., Wakefield R., Gerards A.H., et al. A randomised, double-blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis (2005) [Epub ahead of print]
32. Sieper J., Fendler C., Laitko S., Sorensen H., Gripenberg-Lerche C., Hiepe F., et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum 42 (1999) 1386-1396
33. Wakefield D., McCluskey P., Verma M., Aziz K., Gatus B., and Carr G. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 42 (1999) 1894-1897
34. Smieja M., MacPherson D.W., Kean W., Schmuck M.L., Goldsmith C.H., Buchanan W., et al. Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis 60 (2001) 1088-1094
35. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., LeClercq S., Chiu P., Yan A., et al. A six-month randomized, controlled, double-blind, doseresponse comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46 (2002) 766-773
36. Haibel H., Brandt J., Rudwaleit M., Soerensen H., Sieper S., and Braun J. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 42 (2003) 1018-1020
37. Van den Bosch F., Kruithof E., Baeten D., Herssens A., De Keyser F., Mielants H., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46 (2002) 755-765
38. Pamuk O.N., Harmandar O., Tosun B., Yoruk Y., and Cakir N. A patient with ankylosing spondylitis who presented with chronic necrotising aspergillosis. Report on one case and review of the literature. Clin Rheumatol. En prensa (2005)
39. Baeten D., Kruithof E., Van den Bosch F., Van den Bossche N., Herssens A., Mielants H., et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?. Ann Rheum Dis 62 (2003) 829-834
40. Ferraro-Peyret C., Coury F., Tebib J.G., Bienvenu J., and Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6 (2004) 535-543
41. De Keyser F., Baeten D., Van den Bosch F., Kruithof E., Verbruggen G., Mielants H., et al. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis. Drugs 64 (2004) 2793-2811